The George Institute For Global Health
Global
United Kingdom
India
China
Australia

Home

Found 358 results
Filters: Author is Anushka Patel
2010
Clarke P, Glasziou P, Patel A, et al. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Medicine. 2010;7:e1000236.
Patel A, Neal B, Chalmers J. Event rates in trials of patients with type 2 diabetes. Journal of the American Medical Association (JAMA). 2010;303:732; author reply 733.
Razavian M, Heeley E, Perkovic V, et al. Management of chronic kidney disease in Australian general practice (the AusHEART Study). 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology. 2010.
Li Q, Chalmers J, Czernichow S, et al. Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2010;53:2320-7.
Chalmers J, Colagiuri S, Cooper M, et al. Protection against cardiovascular and renal disease in type 2 diabetes: ADVANCEs in the control of blood pressure using Preterax and Diamicron MR. Issue IV. France: Wolters Kluwer Health France; 2010.
Liu H, Patel A, Brown A, et al. Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk. BMC Public Health. 2010;10:458.
Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine. 2010;363:1410-8.
Patel A. [Symposium] Trials of the cardiovascular polypill. In: 21st Great Wall International Congress of Cardiology. 21st Great Wall International Congress of Cardiology. Beijing, China; 2010.
Barzi F, Woodward M, Czernichow S, et al. The discrimination of dyslipidaemia using anthropometric measures in ethnically diverse populations of the Asia-Pacific Region: the Obesity in Asia Collaboration. Obesity Reviews. 2010;11:127-36.
Zoungas S, Chalmers J, Kengne APascal, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Research and Clinical Practice. 2010;89:126-33.
Kengne APascal, Patel A, Colagiuri S, et al. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax. Diabetologia. 2010;53:821-31.
2009
Chow CK, Patel A. A global view of cardiovascular risk factors. In: Tonkin A, ed. Therapeutic Strategies in Lipid Disorders. Therapeutic Strategies in Lipid Disorders. Oxford: Atlas Medical Publishing; 2009:p. 1-14.
Peiris D, Joshi R, Webster RJ, et al. A novel electronic decision support system to assist general practitioners in cardiovascular disease risk management – a pilot evaluation. 57th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand. 2009;18(Suppl 3):S269.
Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. Journal of the American Society of Nephrology. 2009;20:1813-21. .
Peiris D, Joshi R, Webster RJ, et al. An electronic clinical decision support tool to assist primary care providers in cardiovascular disease risk management: development and mixed methods evaluation. Journal of Medical Internet Research. 2009;11:e51.
Peiris D, Patel A, Cass A, et al. Cardiovascular disease risk management for Aboriginal and Torres Strait Islander peoples in primary health care settings: findings from the Kanyini Audit. Medical Journal of Australia. 2009;191:304-9. .
Patel A. Cardiovascular risk in Australians and Indians: lessons from comparative studies. In: 6th Indo-Australian Biotechnology Conference. 6th Indo-Australian Biotechnology Conference. Hyderabad, India; 2009.
Zoungas S, Chalmers J, Patel A. Cardiovascular risk in Type 2 diabetes – reflecting on the ADVANCE study. Review. European Endocrinology. 2009;5:42-46. .
Zoungas S, Chalmers J, Patel A. Cardiovascular risk in Type 2 diabetes – reflecting on the ADVANCE study. US Endocrinology. 2009;5:95-9. .
Turnbull F, Arima H, Heeley E, et al. Cardiovascular risk management among female and male patients in Australian General Practice: the AusHEART study. 57th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand. 2009;;8(Suppl 3):S272.
Patel A. Cardiovascular risk – who should we treat and how much should we stratify. Heart. 2009;95:783-4. .
de Galan BE, Zoungas S, J C, et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2009;52:2328-36.
Zoungas S, de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes CareDiabetes Care. 2009;32:2068-74.
Heeley E, Peiris D, Weekes A, et al. Current prescribing of Blood Pressure lowering and statin therapies in Australian general practice according to risk level using new guidelines for cardiovascular risk assessment. 57th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand. 2009;18(Suppl 3):S280.
Beulens JW, Patel A, Vingerling JR, et al. Effects of blood pressure lowering and intensive glucose control on incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised